Leor Perl

When the parents of an 8-year-old boy reached out, researchers at Tel Aviv University responded with science. A team from the Gray Faculty of Medical & Health Sciences | הפקולטה למדעי הרפואה והבריאות ע"ש גריי, led by Prof. Moran Rubinstein and Prof. Karen B. Avraham, developed the first mouse model for an extremely rare and fatal genetic disease affecting just 40 people worldwide. This model now enables deeper understanding of the disease and offers a platform to test new drug and gene therapies, bringing real hope to patients and families: https://lnkd.in/erK4dd3A #rarediseases #geneticdiseases #genetherapy #geneinnovation #medtech #healthtech #healthinnovation #innovation

47

‏1‏ ‏תגובה‏

Israel can either buy the algorithms that will rewrite medicine or build them. We do better when we build. In my new op-ed in The Jerusalem Post, I outline how Israel can lead the AI‑bio convergence with world‑class talent, deep real‑world data, GMP scale, and pragmatic regulation. Full piece: https://lnkd.in/gH2efe5F The momentum is here: Biolojic Design, Ltd. is programming antibodies. Immunai is mapping the immune system at single‑cell resolution. Aidoc and Viz.ai are moving life‑saving decisions faster in hospitals. At Somite AI.ai, we're developing AI foundation models for human stem cells to drive novel cell therapies at scale. If we align policy with execution, capturing even five percent of this value chain adds a Mobileye‑scale contributor to GDP. Let’s lead! Teva Pharmaceuticals, Pluri #AI #Biotech #CellTherapy #Israel #Healthcare

71

‏6‏ ‏תגובות‏

Tech continues to drive Israel’s economic resilience, but beneath the surface the ecosystem is showing signs of strain and health tech is feeling the pressure most. The announcement of clinical AI company Aidoc's recent $150 million raise, backed by General Catalyst, Square Peg, nVentures (NVIDIA’s venture capital arm), and four major U.S. health systems, is a sign of what is still possible: when the science is solid, the platform is ready, and the value is global, capital will follow. This is proven by the over 45 million patients currently benefitting from Aidoc's integration across more than 150 health systems. Aidoc’s success is an outlier today, but it should be the model. As the largest sector in Israeli innovation, with over 1,600 companies, health tech should be a source of strength. Instead, in the first half of 2025, it drew just $630 million in private funding — the lowest total in five years. Median deal sizes are shrinking, and time from seed to Series A has stretched to 54 months, pointing to deep structural challenges rather than a short-term slowdown. Capital is flowing elsewhere, toward sectors with faster cycles and clearer paths to scale. Cybersecurity raised $2.2 billion with a median round size of $25 million in H1 2025, while business software led all sectors with $3.2 billion. Health tech is struggling to compete for attention, investment, and talent. These trends are part of a broader shift. Israel’s global innovation position is narrowing, infrastructure hasn’t kept pace with the needs of deep tech, and overreliance on a few sectors is leaving others under-supported. Talent shortages and limited access to global markets are compounding the pressure. At Startup Nation Central, we are seeing this firsthand. Through our work with the 8400 The Health Network Health Network and across the ecosystem, the signals are clear. Health tech is underfunded and underprioritized at a time when its relevance has never been greater. Still, the fundamentals are here. Israel has a strong scientific foundation, a deep pool of entrepreneurial talent, a world-class healthcare system, and health professionals with a track record of innovation. Add to that a growing global demand for health solutions, and the potential is clear. With targeted investment, a renewed focus on translational research, and the right strategic partnerships, health tech can not only recover but take the lead as Aidoc has. The opportunity is real and so is the urgency to act on it. 

108

‏9‏ ‏תגובות‏

𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗯𝗮𝗿𝗿𝗶𝗲𝗿𝘀 𝗮𝗿𝗲 𝗼𝗳𝘁𝗲𝗻 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲 𝘄𝗲 𝘁𝗵𝗶𝗻𝗸 𝗼𝗳 𝘄𝗵𝗲𝗻 𝗶𝘁 𝗰𝗼𝗺𝗲𝘀 𝘁𝗼 𝗮𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀, 𝗯𝘂𝘁 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀’ 𝗻𝗲𝗲𝗱𝘀 𝗰𝗮𝗻 𝗴𝗼 𝗯𝗲𝘆𝗼𝗻𝗱 𝘁𝗵𝗮𝘁. Axios Global Head of Access Solutions, Omer Karfis, reminds us that patient support isn’t always about money. Some need emotional encouragement. Others need education or the chance to connect with people who truly understand their journey. Every patient’s path is different, and the right kind of support can make all the difference in helping them access and complete their treatment course.  🔗 Learn more about how Axios adapts access solutions to patient realities: https://lnkd.in/dDFTwkkk  #NeverStandStill #HealthcareAccess #AccesstoMedicine #AccesstoHealthcare

61

IVC presented a special analysis at the AI Digital Health conference hosted by People & Computers. The study examined active companies in the field, their funding, and other relevant factors. According to the data, 55% of Israeli AI companies focus on enterprise software and infrastructure, while over 300 companies (13%) work in digital health. The Israeli digital health cluster includes 564 companies. Only 22 companies have more than 100 employees, indicating that the ecosystem is still relatively young. More than half of the companies are at the Seed or R&D stage. On the other hand, 44% are selling products to their markets. There are 338 Israeli AI companies focused on digital health, with 200 of them founded in the past five years. Israeli tech companies raised $93 billion in 6554 deals. Israeli AI companies raised $50 billion in this period. AI digital health companies raised $3.5 billion.

30